grant

Immunocompetent in vivo CRISPR screening to identify key transcription factors which enhance persistence and efficacy of CAR-T cells in cancer

Organization UKRILocation United Kingdom
UKRIUK ResearchGrantActive
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Description preview

Chimeric antigen receptor T cells (CAR-Ts) is an exciting treatment where a patient's own immune cells are engineered in the lab to recognise tumour. These cells are then given back to patients by drip where they live and grow in the body, and can find and kill cancer cells. CAR-Ts have been particularly effective in children with acute…

🔒

Full details available on the Agency plan

Unlock the complete grant description, eligibility criteria, contract value, evaluation details and apply link — plus alerts, pipeline tracking, and CSV export.

Start 7-day free trial — $29.99/mo →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →

Explore more

📍 More grants in United Kingdom🏷 More UKRI opportunities🏷 More UK Research opportunities🏷 More Grant opportunities🏢 All ukri_grants opportunities
Immunocompetent in vivo CRISPR screening to identify key transcription factors which enhance persistence and efficacy of | Dev Procure